Reltecimod sodium
Reltecimod sodium (AB-103 sodium) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod sodium has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod sodium modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod sodium can be used to research necrotizing soft-tissue infections (NSTIs).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1943755-99-4
- 分子式: C46H71N10NaO15S
- 分子量:1059.17
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)[2]
-
Dosage:1.25 or 5 mg/kg
-
Administration:i.v.; single dosage; at 4 h post infection
-
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.
Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)[2]
-
Dosage:2.5 or 5 mg/kg
-
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
-
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.
Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.
Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2]
-
Dosage:1.25, 2.5, or 5 mg/kg
-
Administration:i.v.; single dosage
-
Result:Increased day 7 survival by up to 100%.
化学情報
-
CAS 番号 1943755-99-4
-
分子量 1059.17
-
分子式 C46H71N10NaO15S
-
別名
AB-103 sodium
-
配列
{d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala}
-
シーケンスの短縮
{d-Ala}-SPMLVAYD-{d-Ala}
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)